Daltro P S, Barreto B C, Silva P G, Neto P Chenaud, Sousa Filho P H F, Santana Neta D, Carvalho G B, Silva D N, Paredes B D, de Alcantara A C, Freitas L A R, Couto R D, Santos R R, Souza B S F, Soares M B P, Macambira S G
Center for Biotechnology and Cell Therapy, Salvador, BA, Brazil; Multicentric Program in Biochemistry and Molecular Biology, Federal University of Bahia, Salvador, BA, Brazil.
Center for Biotechnology and Cell Therapy, Salvador, BA, Brazil; Faculty of Biology, Federal University of Bahia, Salvador, BA, Brazil.
Cytotherapy. 2017 Oct;19(10):1176-1188. doi: 10.1016/j.jcyt.2017.07.002. Epub 2017 Aug 8.
Obesity is associated with numerous cardiac complications, including arrhythmias, cardiac fibrosis, remodeling and heart failure. Here we evaluated the therapeutic potential of mesenchymal stromal cells (MSCs) and their conditioned medium (CM) to treat cardiac complications in a mouse model of high-fat diet (HFD)-induced obesity.
After obesity induction and HFD withdrawal, obese mice were treated with MSCs, CM or vehicle. Cardiac function was assessed using electrocardiography, echocardiography and treadmill test. Body weight and biochemical parameters were evaluated. Cardiac tissue was used for real time (RT)-polymerase chain reaction (PCR) and histopathologic analysis.
RESULTS/DISCUSSION: Characterization of CM by protein array showed the presence of different cytokines and growth factors, including chemokines, osteopontin, cystatin C, Serpin E1 and Gas 6. HFD-fed mice presented cardiac arrhythmias, altered cardiac gene expression and fibrosis reflected in physical exercise incapacity associated with obesity and diabetes. Administration of MSCs or CM improved arrhythmias and exercise capacity. This functional improvement correlated with normalization of GATA4 gene expression in the hearts of MSC- or CM-treated mice. The gene expression of connexin 43, troponin I, adiponectin, transforming growth factor (TGF) β, peroxisome proliferator activated receptor gamma (PPARγ), insulin-like growth factor 1 (IGF-1), matrix metalloproteinase-9 (MMP9) and tissue inhibitor of metalloproteinases 1 (TIMP1) were significantly reduced in MSCs, but not in CM-treated mice. Moreover, MSC or CM administration reduced the intensity of cardiac fibrosis.
Our results suggest that MSCs and CM have a recovery effect on cardiac disturbances due to obesity and corroborate to the paracrine action of MSCs in heart disease models.
肥胖与多种心脏并发症相关,包括心律失常、心脏纤维化、重塑和心力衰竭。在此,我们评估了间充质基质细胞(MSCs)及其条件培养基(CM)在高脂饮食(HFD)诱导的肥胖小鼠模型中治疗心脏并发症的潜在疗效。
在诱导肥胖并停止高脂饮食后,对肥胖小鼠进行MSCs、CM或赋形剂治疗。使用心电图、超声心动图和跑步机试验评估心脏功能。评估体重和生化参数。心脏组织用于实时(RT)-聚合酶链反应(PCR)和组织病理学分析。
结果/讨论:通过蛋白质阵列对CM进行表征,结果显示存在不同的细胞因子和生长因子,包括趋化因子、骨桥蛋白、胱抑素C、丝氨酸蛋白酶抑制剂E1和Gas 6。喂食HFD的小鼠出现心律失常、心脏基因表达改变和纤维化,这反映在与肥胖和糖尿病相关的运动能力丧失上。给予MSCs或CM可改善心律失常和运动能力。这种功能改善与接受MSCs或CM治疗的小鼠心脏中GATA4基因表达的正常化相关。连接蛋白43、肌钙蛋白I、脂联素、转化生长因子(TGF)β、过氧化物酶体增殖物激活受体γ(PPARγ)、胰岛素样生长因子1(IGF-1)、基质金属蛋白酶-9(MMP9)和金属蛋白酶组织抑制剂1(TIMP1)的基因表达在接受MSCs治疗的小鼠中显著降低,但在接受CM治疗的小鼠中未降低。此外,给予MSCs或CM可降低心脏纤维化的程度。
我们的结果表明,MSCs和CM对肥胖引起的心脏紊乱具有恢复作用,并证实了MSCs在心脏病模型中的旁分泌作用。